Correlating chemical sensitivity and basal gene expression reveals mechanism of action

Nature Chemical Biology

Volumn 12, Issue 2, 2016, Pages 109-116

  Rees, Matthew G ^a   Seashore Ludlow, Brinton ^a,c   Cheah, Jaime H ^a,d   Adams, Drew J ^a,e   Price, Edmund V ^a,c   Gill, Shubhroz ^a   Javaid, Sarah ^b   Coletti, Matthew E ^a   Jones, Victor L ^a   Bodycombe, Nicole E ^a,f   Soule, Christian K ^a,d   Alexander, Benjamin ^a   Li, Ava ^a   Montgomery, Philip ^a   Kotz, Joanne D ^a   Hon, C Suk Yee ^a   Munoz, Benito ^a   Liefeld, Ted ^a,g   Dancík, Vlado ^a   Haber, Daniel A ^b   Clish, Clary B ^a   Bittker, Joshua A ^a   Palmer, Michelle ^a,h   Wagner, Bridget K ^a   Clemons, Paul A ^a   Shamji, Alykhan F ^a   Schreiber, Stuart L ^a   more..

^a BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h IMMUNOGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYL COENZYME A DESATURASE; CYTOTOXIC AGENT; FATTY ACID DESATURASE 2; ML 239; UNCLASSIFIED DRUG; AFLATOXIN; AUSTOCYSTIN D; MOLECULAR LIBRARY;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER CELL LINE; CANCER STEM CELL; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG MECHANISM; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; BREAST NEOPLASMS; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER SIMULATION; DRUG DELIVERY SYSTEM; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; MOLECULAR LIBRARY; PHARMACOLOGY; PRINCIPAL COMPONENT ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

AFLATOXINS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; COMPUTER SIMULATION; DRUG DELIVERY SYSTEMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR STRUCTURE; PRINCIPAL COMPONENT ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; SMALL MOLECULE LIBRARIES;

EID: 84955378277     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.1986     Document Type: Article

References (49)

1. Hughes, J.P., Rees, S., Kalindjian, S.B. & Philpott, K.L. Principles of early drug discovery. Br. J. Pharmacol. 162, 1239-1249 (2011).
2. Schenone, M., Daník, V., Wagner, B.K. & Clemons, P.A. Target identification and mechanism of action in chemical biology and drug discovery. Nat. Chem. Biol. 9, 232-240 (2013).
3. Swinney, D.C. & Anthony, J. How were new medicines discovered Nat. Rev. Drug Discov. 10, 507-519 (2011).
4. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545-15550 (2005).
5. Hughes, T.R. et al. Functional discovery via a compendium of expression profiles. Cell 102, 109-126 (2000).
6. Lamb, J. et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929-1935 (2006).
7. Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-607 (2012).
8. Basu, A. et al. An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell 154, 1151-1161 (2013).
9. Garnett, M.J. et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570-575 (2012).
10. Guo, W. et al. Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition. Cancer Res. 65, 10006-10015 (2005).
11. Papillon-Cavanagh, S. et al. Comparison and validation of genomic predictors for anticancer drug sensitivity. J. Am. Med. Inform. Assoc. 20, 597-602 (2013).
12. Shoemaker, R.H. The NCI60 human tumour cell line anticancer drug screen. Nat. Rev. Cancer 6, 813-823 (2006).
13. Haibe-Kains, B. et al. Inconsistency in large pharmacogenomic studies. Nature 504, 389-393 (2013).
14. Daník, V. et al. Connecting small molecules with similar assay performance profiles leads to new biological hypotheses. J. Biomol. Screen. 19, 771-781 (2014).
15. Adams, D.J. et al. NAMPT is the cellular target of STF-31-like small-molecule probes. ACS Chem. Biol. 9, 2247-2254 (2014).
16. Zhai, D., Jin, C., Satterthwait, A.C. & Reed, J.C. Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins. Cell Death Differ. 13, 1419-1421 (2006).
17. Franceschini, A. et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res. 41, D808-D815 (2013).
18. Benetatos, C.A. et al. Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-B activation, and is active in patient-derived xenograft models. Mol. Cancer Ther. 13, 867-879 (2014).
19. Zoppoli, G. et al. Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents. Proc. Natl. Acad. Sci. USA 109, 15030-15035 (2012).
20. Marks, K.M. et al. The selectivity of austocystin D arises from cell-line-specific drug activation by cytochrome P450 enzymes. J. Nat. Prod. 74, 567-573 (2011).
21. Lafite, P., Dijols, S., Zeldin, D.C., Dansette, P.M. & Mansuy, D. Selective, competitive and mechanism-based inhibitors of human cytochrome P450 2J2. Arch. Biochem. Biophys. 464, 155-168 (2007).
22. Javaid, S. et al. Dynamic chromatin modification sustains epithelial-mesenchymal transition following inducible expression of Snail-1. Cell Rep. 5, 1679-1689 (2013).
23. Rivera, M.I. et al. Selective toxicity of the tricyclic thiophene NSC 652287 in renal carcinoma cell lines: differential accumulation and metabolism. Biochem. Pharmacol. 57, 1283-1295 (1999).
24. Gamage, N. et al. Human sulfotransferases and their role in chemical metabolism. Toxicol. Sci. 90, 5-22 (2006).
25. Glaros, T.G. et al. The "survivin suppressants" NSC 80467 and YM155 induce a DNA damage response. Cancer Chemother. Pharmacol. 70, 207-212 (2012).
26. Nakahara, T. et al. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res. 67, 8014-8021 (2007).
27. Winter, G.E. et al. The solute carrier SLC35F2 enables YM155-mediated DNA damage toxicity. Nat. Chem. Biol. 10, 768-773 (2014).
28. Kamath, A.V., Chong, S., Chang, M. & Marathe, P.H. P-glycoprotein plays a role in the oral absorption of BMS-387032, a potent cyclin-dependent kinase 2 inhibitor, in rats. Cancer Chemother. Pharmacol. 55, 110-116 (2005).
29. Young, L.C. et al. Expression of multidrug resistance protein-related genes in lung cancer: correlation with drug response. Clin. Cancer Res. 5, 673-680 (1999).
30. Adams, D.J. et al. Discovery of small-molecule enhancers of reactive oxygen species that are nontoxic or cause genotype-selective cell death. ACS Chem. Biol. 8, 923-929 (2013).
31. Long, J.Z. et al. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat. Chem. Biol. 5, 37-44 (2009).
32. Nomura, D.K. et al. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 140, 49-61 (2010).
33. Germain, A.R. et al. Identification of a selective small molecule inhibitor of breast cancer stem cells. Bioorg. Med. Chem. Lett. 22, 3571-3574 (2012).
34. Polyak, K. & Weinberg, R.A. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev. Cancer 9, 265-273 (2009).
35. Taube, J.H. et al. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc. Natl. Acad. Sci. USA 107, 15449-15454 (2010).
36. Sprecher, H. Metabolism of highly unsaturated n-3 and n-6 fatty acids. Biochim. Biophys. Acta 1486, 219-231 (2000).
37. Obukowicz, M.G. et al. Identification and characterization of a novel delta6/delta5 fatty acid desaturase inhibitor as a potential anti-inflammatory agent. Biochem. Pharmacol. 55, 1045-1058 (1998).
38. Catalá, A. Lipid peroxidation of membrane phospholipids generates hydroxy-alkenals and oxidized phospholipids active in physiological and/or pathological conditions. Chem. Phys. Lipids 157, 1-11 (2009).
39. Snyder, F., Lee, T. & Wykle, R.L. Ether-linked lipids and their bioactive species. in Biochemistry of Lipids, Lipoproteins, and Membranes edn. 4 (eds. Vance, D.E. & Vance, J.E.) 233-262 (Elsevier, 2002).
40. Yang, W.S. et al. Regulation of ferroptotic cancer cell death by GPX4. Cell 156, 317-331 (2014).
41. Park, W.J., Kothapalli, K.S., Lawrence, P. & Brenna, J.T. FADS2 function loss at the cancer hotspot 11q13 locus diverts lipid signaling precursor synthesis to unusual eicosanoid fatty acids. PLoS One 6, e28186 (2011).
42. Salt, M.B., Bandyopadhyay, S. & McCormick, F. Epithelial-to-mesenchymal transition rewires the molecular path to PI3K-dependent proliferation. Cancer Discov. 4, 186-199 (2014).
43. Byers, L.A. et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin. Cancer Res. 19, 279-290 (2013).
44. Fischer, E.S. et al. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature 512, 49-53 (2014).
45. Palmer, A.C. & Kishony, R. Opposing effects of target overexpression reveal drug mechanisms. Nat. Commun. 5, 4296 (2014).
46. Yu, C. & Golub, T.R. Multiplex methods to assay mixed cell populations simultaneously. US Patent WO 2013138585 A1 (2013).
47. Cowley, G.S. et al. Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. Sci. Data 1, 140035 (2014).
48. Chen, C. et al. Selective inhibitors of CYP2J2 related to terfenadine exhibit strong activity against human cancers in vitro and in vivo. J. Pharmacol. Exp. Ther. 329, 908-918 (2009).
49. Yang, X. et al. A public genome-scale lentiviral expression library of human ORFs. Nat. Methods 8, 659-661 (2011).